Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Hormones and Carcinogenesis
share announcement

Hormones and Carcinogenesis

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: closed (31 July 2014) | Viewed by 25143

Special Issue Editor

Prof. Dr. Robin Fuchs-Young

E-Mail
Guest Editor
Department of Molecular and Cellular Medicine, College of Medicine and the Institute for Bioscience and Technology, 208 Reynolds Medical Building, Texas A&M Health Science Center College Station, TX 77843-1114, USA

Special Issue Information

Dear Colleagues,

Hormones play a critical role in cancer development in a variety of organs, including breast, uterus, ovary, prostate, testes, liver and others. Recent investigations have revealed that “cross-talk” between hormone and growth factor signaling networks affect the acquisition of the malignant phenotype, often in a tissue specific fashion. Environmental factors acting as hormonal mimics (endocrine disruptors) can alter both genetic integrity and epigenetic programs, and these effects can be further modulated by exposures during specific developmental periods (“windows of susceptibility”). This special issue of Hormones and Carcinogenesis is intended to incorporate a range of topics related to the contributions of steroid and peptide hormones to susceptibility, incidence, progression and treatment of cancer. We invite authors to submit primary papers as well as thoughtful reviews that elucidate mechanisms and pathways of hormonal carcinogenesis and/or that introduce new hypotheses and paradigms.

Prof. Dr Robin Fuchs-Young
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • hormone
  • peptide
  • steroid
  • receptor
  • carcinogenesis
  • signaling/signal transduction
  • cross talk
  • endocrine disruptors

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

190 KiB  
Review
Estrogen Signaling in Lung Cancer: An Opportunity for Novel Therapy
by Christina S. Baik and Keith D. Eaton
Cancers 2012, 4(4), 969-988; https://doi.org/10.3390/cancers4040969 - 25 Sep 2012
Cited by 43 | Viewed by 7305
Abstract
Lung cancer is the leading cause of cancer death in U.S. and represents a major public health burden. Epidemiologic data have suggested that lung cancer in women may possess different biological characteristics compared to men, as evidenced by a higher proportion of never-smokers [...] Read more.
Lung cancer is the leading cause of cancer death in U.S. and represents a major public health burden. Epidemiologic data have suggested that lung cancer in women may possess different biological characteristics compared to men, as evidenced by a higher proportion of never-smokers among women with lung cancer. Emerging data indicate that female hormones such as estrogen and progesterone play a significant role in lung carcinogenesis. It has been reported that estrogen and progesterone receptors are expressed in lung cancer cell lines as well as in patient-derived tumors. Hormone related risk factors such as hormone replacement therapy have been implicated in lung carcinogenesis and several preclinical studies show activity of anti-estrogen therapy in lung cancer. In this review, we summarize the emerging evidence for the role of reproductive hormones in lung cancer and implications for lung cancer therapy. Full article
(This article belongs to the Special Issue Hormones and Carcinogenesis)
933 KiB  
Review
Endometrial Serous Carcinoma: Its Molecular Characteristics and Histology-Specific Treatment Strategies
by Kentaro Nakayama, Naomi Nakayama, Masako Ishikawa and Kohji Miyazaki
Cancers 2012, 4(3), 799-807; https://doi.org/10.3390/cancers4030799 - 07 Aug 2012
Cited by 11 | Viewed by 17374
Abstract
Endometrial cancer is the fourth most common malignancy in women, with most cases being classified as early stage endometrioid tumors that carry a favorable prognosis. The endometrial serous histological subtype (ESC), however, while only accounting for 10% of all endometrial cancers is responsible [...] Read more.
Endometrial cancer is the fourth most common malignancy in women, with most cases being classified as early stage endometrioid tumors that carry a favorable prognosis. The endometrial serous histological subtype (ESC), however, while only accounting for 10% of all endometrial cancers is responsible for a disproportionate number of deaths. Unlike the estrogen-dependent, well differentiated endometrioid tumors, which are commonly associated with a younger age of onset, ESCs are estrogen-independent and tend to present at an advanced stage and in older women. Treatment for ESC entails aggressive surgery and multimodal adjuvant therapy. In this review, we describe the clinical behavior, molecular aspects, and treatment strategies for ESC. Full article
(This article belongs to the Special Issue Hormones and Carcinogenesis)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop